Abstract Library

#4667 Clinical outcomes in patients with typical (TC) and atypical bronchial carcinoids (AC): A 15-year retrospective study from an ENETS Center of Excellence

Introduction: Bronchial neuroendocrine neoplasms (NENs) can be subdivided into TCs, ACs and neuroendocrine carcinomas (NECs). Although a few studies have explored treatment approaches and oncological outcomes, most focus on surgical cohorts, small sample sizes, or mixed groups including TC, AC, and NECs. Real-life cohort data are lacking.

Conference:

Presenting Author: Clement D

Authors: Correia J, Sarker D, Dolly S, Frydman A, Srirajaskanthan R,

Keywords: bronchial carcinoid, treatment pattern, recurrence-free survival, overall survival,

#4666 Merkel cell neuroendocrine carcinoma of the skin: High response rates to short course palliative radiotherapy – Typical clinical scenarios

Introduction: Merkel cell carcinomas (MCC) are a rare, aggressive skin neuroendocrine carcinomas, with peak incidence in the elderly. MCC often presents as a firm, red/purple painless nodule with a short history of increasing size. Surgery is considered the 1st line treatment but elderly patients, in particular, have comorbidities which may preclude radical surgery requiring reconstruction. In advanced MCC, immunotherapy (IO) is 1st line systemic treatment. Chemotherapy is used 2nd line or if contraindications for IO but can be challenging in an elderly population. There may be an emerging role for PRRT due to the presence of somatostatin receptors on MCC. Radiotherapy (RT) can be used for non-surgical candidates, or those with unresectable or metastatic disease. Adjuvant post-operative irradiation (PORT) may provide additional benefit in risk reduction and improves local control.

Conference:

Presenting Author:

Authors: Saunders E, Sizer B, Collins J, Skelly R, Srinivasan G,

Keywords: Merkel cell, skin, radiotherapy,

#4663 CAREFNDR: A phase III, randomised, parallel group, placebo-controlled study to evaluate the efficacy and safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumours

Introduction: Paltusotine is a once-daily, oral, nonpeptide, selective SST2 receptor agonist in development for carcinoid syndrome (CS) treatment. In a Phase 2, open-label, dose-ranging study, paltusotine reduced the frequency and severity of CS symptoms and was well tolerated (NCT05361668).

Conference:

Presenting Author:

Authors: Kim R, Usiskin K, Fan X, Quock T, Mui C,

Keywords: paltusotine, phase 3 trial, somatostatin receptor agonist, neuroendocrine tumour, carcinoid syndrome,

#4641 Case series: Tuberous sclerosis associated pancreatic neuroendocrine tumours at a tertiary centre

Introduction: Tuberous sclerosis (TSC) is an autosomal dominant condition which can increase the risk of pancreatic neuroendocrine tumours (PanNETs) (1). Patients with TSC undergo screening for renal tumours which may include pancreatic imaging (2). There are currently no screening guidelines for PanNETs in patients with TSC.

Conference:

Presenting Author: Frydman A

Authors: Frydman A, Clement D, Srirajaskanthan R,

Keywords: Pancreas neuroendocrine tumour, Tuberous sclerosis,

#4635 Comparison of 18F-DOPA PET/CT and 68Ga-DOTATOC PET/CT and their impact on response to PRRT in midgut neuroendocrine tumours

Introduction: 18F-DOPA PET/CT is a powerful diagnostic test for assessing tumour burden in midgut neuroendocrine tumours (NETs). 68Ga-DOTATOC PET/CT is required for patient selection for PRRT.

Conference:

Presenting Author: Longo M

Authors: Longo M, Coccarelli A, Henry T, Kamoun T, Morbelli S,

Keywords: F-DOPA, Ga-DOTATOC, PRRT, midgut,